Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)

Main Article Content

M Augustin
J Wegtowska
M Lebwohl
C Paul
V Piguet
H Sofen
A Blauvelt
L Peterson
Et al.

Keywords

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Dermira.

Copyright 2018 SKIN